June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Multimodal retinal imaging evaluation may predict the response to eplerenone therapy in central serous chorioretinopathy
Author Affiliations & Notes
  • Riccardo Sacconi
    Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Milan, Italy, Milano, Milano, Italy
    Ophthalmology, University of Verona, University hospital of Verona, Verona, Italy, Verona, Italy
  • Giovanni Baldin
    Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Milan, Italy, Milano, Milano, Italy
  • Adriano Carnevali
    Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Milan, Italy, Milano, Milano, Italy
    Ophthalmology, University of “Magna Graecia”, Catanzaro, Italy, Catanzaro, Italy
  • Lea Querques
    Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Milan, Italy, Milano, Milano, Italy
  • Alessandro Rabiolo
    Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Milan, Italy, Milano, Milano, Italy
  • Maria Vittoria Cicinelli
    Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Milan, Italy, Milano, Milano, Italy
  • Giorgio Panozzo
    Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Milan, Italy, Milano, Milano, Italy
  • Giorgio Marchini
    Ophthalmology, University of Verona, University hospital of Verona, Verona, Italy, Verona, Italy
  • Francesco Bandello
    Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Milan, Italy, Milano, Milano, Italy
  • Giuseppe Querques
    Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Milan, Italy, Milano, Milano, Italy
  • Footnotes
    Commercial Relationships   Riccardo Sacconi, None; Giovanni Baldin, None; Adriano Carnevali, None; Lea Querques, None; Alessandro Rabiolo, None; Maria Vittoria Cicinelli, None; Giorgio Panozzo, None; Giorgio Marchini, Alcon (C), Allergan Inc (C), Bausch and Lomb (C), Santen (C); Francesco Bandello, Alcon (C), Alimera Sciences (C), Allergan Inc (C), Bausch And Lomb (C), Bayer Shering-Pharma (C), Farmila-Thea (C), Genentech (C), Hoffmann-La-Roche (C), NovagaliPharma (C), Novartis (C), Sanofi-Aventis (C), Thrombogenics (C), Zeiss (C); Giuseppe Querques, Alimera Sciences (C), Allergan Inc (C), Bayer Shering-Pharma (C), Heidelberg (C), Novartis (C), Zeiss (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 5936. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Riccardo Sacconi, Giovanni Baldin, Adriano Carnevali, Lea Querques, Alessandro Rabiolo, Maria Vittoria Cicinelli, Giorgio Panozzo, Giorgio Marchini, Francesco Bandello, Giuseppe Querques; Multimodal retinal imaging evaluation may predict the response to eplerenone therapy in central serous chorioretinopathy
      . Invest. Ophthalmol. Vis. Sci. 2017;58(8):5936.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the effects of oral eplerenone in treatment-naïve patients affected by central serous chorioretinopathy (CSC), and to identify predictive factors associated with a better response to eplerenone by multimodal retinal imaging.

Methods : Interventional non-randomized clinical study. Twenty-eight treatment-naïve CSC eyes were prospectively enrolled and treated with oral eplerenone for 1 to 3 months. Primary outcomes included the percentage of eyes achieving complete resolution of subretinal fluid (SRF) on structural optical coherence tomography (OCT) after treatment, and changes in best-corrected visual acuity (BCVA) and central macular thickness (CMT). Secondary outcomes included the presence of pathological findings on indocyaine green angiography (ICGA) and OCT-angiography (OCT-A) at baseline associated with different response to eplerenone treatment.

Results : Seventeen eyes (61%) demonstrated total reabsorption of SRF on structural OCT, 5 eyes (18%) presented a partial response to eplerenone therapy and 6 eyes (21%) showed no response. Eplerenone treatment has also proven efficacy in reducing CMT and improving BCVA (p<0.001). The complete response to eplerenone treatment was associated with absence of CNV at OCT-A and the presence of hotspot at ICGA (p<0.001 and p=0.002, respectively). None of 7 eyes with CNV in OCT-A imaging had a complete response to eplerenone and none of 3 eyes without hotspot at ICGA showed a complete response to the treatment.

Conclusions : Our results confirmed the effectiveness of eplerenone therapy in treatment-naïve CSC. Multimodal retinal imaging allowed us to propose predictive factors (i.e. absence of CNV on OCT-A and presence hotspot on ICGA) for better response to eplerenone.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×